Merck: launches phase III trial in lung cancer
KRAS is one of the most common cancer mutations, and KRAS G12C is the most common KRAS mutation in NSCLC patients," said Dr. Marjorie Green, Senior Vice President and Head of Global Oncology and Clinical Development at Merck Research Laboratories.
Merck has launched a Phase 3, randomized, double-blind, multicenter clinical trial (NCT06345729) evaluating MK-1084 once-daily + Keytruda administered once every three weeks, versus Keytruda + placebo.
The study's primary endpoints are progression-free survival and overall survival, and key secondary endpoints include objective response rate and duration of response.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction